the Jakinibs, for use in ALS treatment based on her data identifying a novel mechanism by which the immune system contributes to disease progression. In October 2021, she received the esteemed NIH Director’s Transformative Award as the leader of an interdisciplinary team from Michigan Medicine and the School of Public Health that employs novel approaches to “omics” clinical data with the goal of making ALS a preventable disease. Announcing the grant, Dr. Francis Collins, who was then NIH Director, stated that these “innovative researchers have the potential to transform the biomedical field,” going on to say that recipients of the award “will revolutionize our approaches to biomedical research through their groundbreaking work.” Dr. Feldman also founded the University of Michigan ALS Consortium, establishing a biorepository for ALS, which has facilitated identification of epigenetic, transcriptomic, metabolomic, and immunological unique signatures in ALS along with potential biomarkers. Her work has also identified new ALS therapeutic targets, as well as environmental toxins that are potentially risk factors for the disease. Neuropathy and diabetes complications Feldman is equally known internationally for her work in diabetes complications, particularly peripheral neuropathy. She received the Juvenile Diabetes Research Foundation Mary Jane Kugel Award twice (2003 and 2005), the American Diabetes Association Lifetime Achievement Award (2006), Endocrine Society Gerald D. Aurbach Award for Outstanding Translational Research (2017), and the Peripheral Nerve Society Alan J. Gebhart Prize for Excellence in Peripheral Nerve Research (2019). Her efforts over the past 30 years in this area have changed practice guidelines for diagnosing early prediabetic neuropathy. Her early work developing the Michigan Neuropathy Screening Instrument (MNSI) has led to the tool’s widespread global use to diagnose neuropathy. She has uncovered important roles for lipids and the metabolic syndrome in neuropathy pathogenesis in prediabetes and type 2 diabetes and is an author on the American Diabetes Association Guidelines on the treatment of diabetic neuropathy. She is currently developing risk assessment tools to inform the care of COVID-19 patients with type 2 diabetes during this health crisis as well as pandemics to come, while also studying the neurological implications of patients with Long COVID. Brain health and Alzheimer’s disease Dr. Feldman is leading efforts to understand how metabolic dysfunction drives neurologic complications and impacts brain health. Her team found a correlation between diabetes and Alzheimer’s disease, and she has initiated a landmark study to understand how diabetes and obesity contribute to dementia. Feldman’s lab